Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

about

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

Item

http://www.wikidata.org/entity/Q55177621

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Evaluation of minimal residual ...... patients with AL amyloidosis.

@en

Evaluation of minimal residual ...... patients with AL amyloidosis.

@nl

type

Item

label

Evaluation of minimal residual ...... patients with AL amyloidosis.

@en

Evaluation of minimal residual ...... patients with AL amyloidosis.

@nl

prefLabel

Evaluation of minimal residual ...... patients with AL amyloidosis.

@en

Evaluation of minimal residual ...... patients with AL amyloidosis.

@nl

P1476

Evaluation of minimal residual ...... patients with AL amyloidosis.

@en

P2093

Bruno Paiva

http://www.w3.org/2001/XMLSchema#string

Despina Fotiou

http://www.w3.org/2001/XMLSchema#string

Dimitrios C Ziogas

http://www.w3.org/2001/XMLSchema#string

Evangelos Eleutherakis-Papaiakovou

http://www.w3.org/2001/XMLSchema#string

Evangelos Terpos

http://www.w3.org/2001/XMLSchema#string

Ioannis P Trougakos

http://www.w3.org/2001/XMLSchema#string

Ioannis V Kostopoulos

http://www.w3.org/2001/XMLSchema#string

Magdalini Migkou

http://www.w3.org/2001/XMLSchema#string

Maria Gavriatopoulou

http://www.w3.org/2001/XMLSchema#string

Maria Roussou

http://www.w3.org/2001/XMLSchema#string

P2860

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction

Recent advances in the management of AL Amyloidosis.

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.

Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services.

Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.

Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.

First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis.

P2888

s41408-018-0086-3

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41408-018-0086-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

Efstathios Kastritis

P577

2018-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104152512

http://www.w3.org/2001/XMLSchema#string

P698

29795385

http://www.w3.org/2001/XMLSchema#string

P932

5967299

http://www.w3.org/2001/XMLSchema#string